GlassScriptPhysician profile
Brianne Elizabeth Smith
NPI 1235666538
$1,234.59
in general payments reported to CMS, 2019-2025
20 companies · $407 in 2025
The $407 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $71.44 · 2022: $235 · 2023: $288 · 2024: $233 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $928.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $928.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $187.32 | 2023-2025 | |
| Abbvie INC. | $162.15 | 2022-2025 | Vraylar, Qulipta, Creon |
| Pfizer INC. | $159.22 | 2022-2025 | |
| Glaxosmithkline, LLC. | $123.65 | 2022-2025 | Shingrix, Trelegy Ellipta, Bexsero |
| Novo Nordisk INC | $112.85 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $99.03 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $61.02 | 2022-2025 | Airsupra, Breztri |
| Amgen INC. | $58.60 | 2021-2023 | Prolia, Evenity |
| Biohaven Pharmaceutical Holding Company LTD. | $44.45 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $35.51 | 2023-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $29.05 | 2023-2025 | |
| Astellas Pharma US INC | $21.37 | 2024 | Veozah |
| Sumitomo Pharma America, INC. | $20.05 | 2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $19.86 | 2022 | |
| Dexcom, INC. | $18.73 | 2025 | Dexcom G6 Transmitter |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $17.45 | 2024 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $16.95 | 2024 | Yupelri |
| Merck Sharp & Dohme LLC | $16.43 | 2025 | Gardasil 9, Capvaxive, Enflonsia |
| Boston Scientific Corporation | $15.77 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $15.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brianne Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.